ImmunityBio Reports Continued Execution and Sales Momentum With $113 Million of Preliminary Net Product Revenue—a 700% increase year-over-year

ImmunityBio, Inc. (NASDAQ: IBRX), a vertically-integrated commercial stage biotechnology company, announced today preliminary ...

WATCH: IDF unveils rare footage of clear ambush, close-quarters gunfight with Hamas

Six Hamas fighters were spotted by IDF surveillance on Tuesday, trying to surprise and ambush the military. After ...
Investing.com India

ImmunityBio stock soars on strong sales growth and global approvals

Investing.com -- ImmunityBio (NASDAQ:IBRX) stock surged 28% Thursday after the company reported preliminary 2025 net product revenue of approximately $113 million, representing a 700% increase ...
pv magazine International

Rising silver prices drive China’s Longi shift to copper-metallized solar cells

China’s Longi says it will begin mass production of base-metal PV modules in the second quarter of 2026 as rising silver ...

DOJ releases huge set of Epstein files with many mentions of Trump, says more documents to come

The Justice Department early Tuesday released more than 11,000 additional documents and photos from the Jeffrey Epstein files ...

ImmunityBio gains as Anktiva powers over 400% Q4 sales growth

ImmunityBio (IBRX) stock rises as the company records over 400% YoY groiwth in Q4 net product revenue thanks to its cancer ...

‘Spat at, pushed, punched’: medics tell of soaring levels of violence in hospitals

Doctors and nurses blame inaction by police and the NHS for mounting toll of physical and sexual abuse ...
Open Access Government

Beyond microbial fermentation: Reimagining biomanufacturing for low-resource environments

Traditional biomanufacturing is based on microbial or mammalian cell culture, plants can be grown in bioreactors and hold ...

ImmunityBio: Why I Am Upgrading To A Buy For 2026

ImmunityBio, Inc. is upgraded to Buy reflecting improving Anktiva data & potential label expansions in NMIBC and NSCLC. Read ...